metaEvidence - overview


			deaths (OS)
mML - NA - all population metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - all population
versus Ipilimumab (10 mg/kg)
	nivolumab alone vs. Ipilimumab (10 mg/kg)	1	-243 [-793; 307] /10000 100/453 vs. 111/453
versus placebo
	nivolumab alone vs. placebo	1	-
mML - NA - PDL1 positive metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - PDL1 positive
mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population
versus ipilimumab alone
	nivolumab alone vs. ipilimumab alone	1	NaN [NaN; NaN] /10000 0/0 vs. 0/0
mML - L1 - BRAF mutant metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF mutant
mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild
versus dacarbazine
	nivolumab alone vs. dacarbazine	1	-2234 [-3124; -1345] /10000 50/210 vs. 96/208
mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population
versus Standard of Care (SoC)
	nivolumab alone vs. Standard of Care (SoC)	1	NaN [NaN; NaN] /10000 0/0 vs. 0/0
mML - L2 - BRAF mutant metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - BRAF mutant